BioWorld

Oct. 28, 2005

ZymoGenetics Starts Pivotal rhThrombin Phase III Study

Nearly three months after raising $135 million to move its lead blood-clotting agent into a pivotal study, ZymoGenetics Inc. started the Phase III trial of recombinant human Thrombin (rhThrombin) in surgery patients. (BioWorld Today) Read More

NicOx Licenses Respiratory Drug To Topigen For 54.9M

Antibiotics Developers Report New Compounds, Mechanisms

Meeting Looks At Financing Matters, Strategies For Exit

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 13, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...